REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Regenxbio (RGNX) Misses Q2 EPS by 24c
August 9, 2021 4:48 PM EDTRegenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.36), $0.24 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $22 million versus the consensus estimate of $29.02 million.
Financial Guidance:
Based on its current operating plan, REGENXBIO expects its balance in... More
